Leovigildo Reyes, MD
Interventional Pain Medicine · Oakland Park, FLNPI 1104810399
Payments from drug & device makers
Across 138 payments — averaging $32.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- MML US, Inc.$763
- Biohaven Pharmaceuticals, Inc.$662
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$660
- AbbVie$530
- IBSA Pharma Inc.$306
- Collegium Pharmaceutical, Inc.$261
- plus $1K from 21 others
What the payments were for
- Travel & lodging$59813%
- Food & beverage$3,92287%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| MML US, Inc. | 4 | $763 |
| Biohaven Pharmaceuticals, Inc. | 7 | $662 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 37 | $660 |
| AbbVie(2 entities) | 16 | $530 |
| IBSA Pharma Inc. | 14 | $306 |
| Collegium Pharmaceutical, Inc. | 13 | $261 |
| Idorsia Pharmaceuticals US Inc | 7 | $248 |
| Biohaven Pharmaceutical Holding Company Ltd. | 6 | $218 |
| Eisai Inc. | 7 | $197 |
| Curonix LLC | 1 | $142 |
| Amneal Pharmaceuticals LLC | 4 | $76 |
| Redhill Biopharma Inc. | 3 | $61 |
| Pfizer | 2 | $53 |
| Valinor Pharma, LLC | 2 | $44 |
| Forte Bio-pharma LLC | 2 | $39 |
| Stryker | 1 | $38 |
| Kowa Pharmaceuticals America, Inc. | 2 | $37 |
| Vertex | 1 | $24 |
| Orexo US, Inc. | 1 | $23 |
| Masimo Corporation | 1 | $23 |
| Nalpropion Pharmaceuticals LLC | 1 | $22 |
| Protega Pharmaceutials Inc | 1 | $18 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| AstraZeneca | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Acella Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$743
- ReActiv8$692
- PNS FREEDOM-4A PERMANENT NEUROSTIMULATOR RECEIVER KIT CHANNEL A$142
- QULIPTA$125
- UBRELVY$124
- Dayvigo$121
- QUVIVIQ$121
How this compares
$4,520 in reported general payments places this provider in the 45th percentile of 278 interventional pain medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxycontinOxycodone Hcl | 136 | $253,767 |
| RelistorMethylnaltrexone Bromide | 59 | $138,435 |
| Xtampza ErOxycodone Myristate | 86 | $94,694 |
| Nurtec OdtRimegepant Sulfate | 24 | $51,933 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 856 | $32,737 |
| Fentanyl | 206 | $31,198 |
| Morphine Sulfate ErMorphine Sulfate | 556 | $28,500 |
| UbrelvyUbrogepant | 11 | $23,700 |
| MovantikNaloxegol Oxalate | 40 | $20,323 |
| BotoxOnabotulinumtoxina | 14 | $18,935 |
| Oxymorphone Hcl ErOxymorphone Hcl | 21 | $13,895 |
| Hydromorphone Hcl | 230 | $13,455 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 414 | $11,910 |
| QuviviqDaridorexant Hcl | 22 | $10,741 |
| LicartDiclofenac Epolamine | 11 | $9,286 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor | $660 | $138,43559 claims |
| Collegium Pharmaceutical, Inc.Xtampza Er, Belbuca | $261 | $99,95499 claims |
| PfizerNurtec Odt | $53 | $51,93324 claims |
| AbbVieUbrelvy, Botox | $530 | $42,63525 claims |
| Redhill Biopharma Inc.Movantik | $61 | $20,32340 claims |
| Hikma Pharmaceuticals USABuprenorphine, Morphine Sulfate, Buprenorphine-Naloxone | $14 | $19,452217 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $248 | $10,74122 claims |
| IBSA Pharma Inc.Licart | $306 | $9,28611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 278 interventional pain medicine providers in Florida.
Other interventional pain medicine in Oakland Park
- Ajay AntonyGainesville$1.9M
- Louis RasoJupiter$1.6M
- Gilbert MbeoOrlando$1.4M
- George BesongOrange City$1.2M
- Gary KaoMiddleburg$1.1M
- Neil EllisTampa$1.1M
- Alexis RentaBoynton Beach$1.1M
- Michael EspositoVero Beach$1M
- Jose RiveraTampa$993K
- Nomen AzeemRiverview$691K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.